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The effect of naltrexone, a long-acting opiate antagonist, on pregnancy was studied by implanting Alzet osmo-minipumps on day 5 of gestation in Sprague-Dawley rats. The pumps contained either 100 mg/ml naltrexone hydrochloride in 0.9% saline delivering 5.6 mglkglhr of drug for a period of 14 days, or saline only. Somatomedin activity was determined on serum obtained from individual mothers, and on pooled blood from fetuses. Delivery occurred under ether anesthesia. Blood was collected by decapitation. A competitive protein binding assay using Multiplication Stimulating activity(MSA) as previously described by Moses, et. al(Endo,104:536,1979 ) was used to determine somatomedin activity. Samples were chromatographed on Sephadex G50 in 1M acetate to remove binding protein before assay. Maternal somatomedin activity was lower in drug treated animals (MD) = 28. 0+-51.3 (n=5) than in controls (MC) = 337+-51.3ng/ml (n=5), pX.069. Fetal somatomedin acivity of control animals measured 3778+-3785 (n=2) vs. 3148+-1454ng/ml (n=2) in those that were drug treated. Maternal weight gain was also unaffected (MC=114.0+-14 vs. MD=116.3 +23.9g ). However, drug treated animals had food intake decreased to 80% of control during the first week after pump implantation.
These data suggest that naltrexone impairs maternal somatomedin production without affecting fetal outcome. Studies are in progress to determine if this effect could be due to the alterations in food intake seen. Production of &hCG is comnonly seen in non-gestational choriocarcinoma and considered a specific hormonal marker of this kind of neoplasm. More rarely ovarian g e m cell tumors have been descri bed producing P-hCG. A 4 11/12 yr old girl had a 2 yr long histoq of abdominal pain, bilateral breast development for 5 months and vaginal bleeding for 9 days. Examination showed a well developed girl with a height 112 cms, weight 21 kg (both at the 85th percentile), evidence of gonadarche (breast development Tanner 4, estrogenization of the external genitalia and vaginal bleeding), and no evidence of adrenarche (absent pubic hair= Tanner 1, not axillary odor nor hair). A large abdominal mass 15x20 cms was palpated. Bone age was 5 6/12 yrs. Pielography and ultrasound exams were cop sistant with an ovarian cystic mass. At laparotomy a 1 3 x 8~7 cms right ovarian cystic multiloculated tumor removed. By punction a citrine clear fluid was obtained which contained the following hormones: F h C G >2,500 mIU/ml, LH 2.9 mIU/ml, FSH 2.0 mIU/ml, estradiol 220 pg/ml, progesterone 40 ng/ml, 17-OHprogesterone >I2 ng/ml, DHEA.S04 54 ng/dl, and prolactin 9.8 ng/ml. The left ovary and uterus were reported "normal". Histology was that of a granulosa cell tumor. All the abnormal clinical findings disappeared. We conclude: 1-The estrogen production of this tumor was the cause of the pseudoprecocious puberty, 2-This neoplasm had a self stimulatory mechanism by producing P-hCG, and 3-p-hCG is a potential hormonal marker for some types of granulosa cell tumors. Five girls and one boy with precocious puberty have been treated for 2-4 yrs with D-TRP-6-LH-RH (0.45-1.5 mcglkglday s.c.). LH and FSH secretion assessed by LRH tests remained suppressed in 4 patients; in 2 "escape" FSH responsiveness was observed after 1% and 3 314 yrs of therapy. In all girls E2 levels remained in the prepubertal range ( < 20 pglml) with occasional transient increases up to 53 pglml. In the boy testosterone levels dropped from 245 to 45 ng/dl on starting therapy and starting 1% yrs later showed some increase (mean testosterone during 3rd year of therapy: 88.11236 ng/dl). Clinica!ly all showed sustained arrest of gonadarche with adrenarche unaffected; 2 girls requir6.d additive antiandrogen therapy. In all growth slowed to prepubertal rate and the BA/CA was decrcased, indicating an improved final height prognosis. There were no undesirable side effects and all patients showed good compliance. It is concluded that at present therapy with superactive LH-RH analogue is the treatment of choice for precocious puberty.
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The efficacy of periodic administration of Decapeptyl microcapsules upon symptoms of PP has been previously reported (Roger et al., ESPE meeting 1984, abstract 22) . A sensitive radioimmuno assay of the analogue was developped using an antiserum raised in rabbit which exhibited unsignificant cross reactivity with native LH-RH or LH-RH fra ments (Mason-Garcia et al. ,Proc.Natl .
Acad. Sci., USA, in press?. Iodinated D-Trp-6-LH-RH was used as a tracer. Fifty p1 antiserum diluted at 1/2500, 50 ~1 tracer, 100 ul standard (or unknown plasma), 100 p1 plasma pool (or phosphate buffer 0.01 M, pH 7.5) were incubated for 24 h. Free and bound were separated by PEG. NSB of the plasma pool and of 40 different child samples were respectively 6.2'0.4 and 6.3c 0.4% (mean+SD). Bo was 20%. Intraassay CV were 12 and 7% for mean plasma levels of 100 and 370 pglml respectively. The detec tion limit was 57 pgfml. Five children received intramuscularly (IM) on days 1, 21 and every 28 days thereafter, 1.5 mg Decapeptyl microcapsules. Plasma levels were on days 3, 7, 14, and 21
(pg/ml, meanrSEM) 312557, 242+65, 145r78 and 171.87. Decapeptyl was undetectable in most of samples on day 28 after injection.
This study demonstrates that significant Decapeptyl levels are maintained for at least 21 days after a single IM injection.
play a role in this decrease we measured catecholamine and vanillylmandelic acid (VMA) excretion in 24 hour urine samples from 39 normal children (N) and from 42 children with precocious puberty (PP).
The results (mean + SEM), grouped according to age and pubertal stage, are shown-in the We conclude that puberty is associated with a decreased urinary catecholamine and V M excretion and that-children with precocious puberty have urinary catecholamine and VMA excretion that is decreased for age but appropriate for pubertal stage. Precocious puberty (PP) in girls with Mc Cune-Albright syndrome has been attributed to autonomous ovarian function and premature activation of the hypothalamo-pituitary-ovarian axis. We report the clinical and hormonal findings in a 5 2/12 year old girl with Mc Cune-Albright syndrome, large ovarian cysts and PP. She initially presented with extremely elevated E2-(1473 pmol/l) and suppressed LH-(11 ng/ml) and FSH-levels below the detection limit. 8 months after initiation of cyproterone acetate therapy, an intravenous LHRH-test showed LH-(56 and 324 ng/ml, basal and stimulated) and FSH-levels (6.8 and 12.6 nglml) well in the pubertal range. 23 days later complete suppression of gonadotropins again was demonstrated. We suggest that the mechanism of PP in girls with Mc Cune-Albright syndrome might involve intermittent activation of the hypothalamo-pituitary axis followed by apparently autonomous ovarian function.
VARIABLE SECRETORY HOPJYONAL PATTERNS IN
